The Council of Scientific and Industrial Research (CSIR) will undertake a two-arm phase-II medical trial to evaluate the security and efficacy of the drug Colchicine for the therapy of Covid-19 sufferers.
Colchicine is used for treating gout and associated inflammatory circumstances. The drug is anticipated to be an essential therapeutic intervention for Covid sufferers with cardiac co-morbidities.
Numerous world research have confirmed now that cardiac problems throughout course of Covid-19 infections and post-Covid syndrome are resulting in lack of many lives, and it’s important to search for new or repurposed medicine.
India is among the largest producers of this key drug Colchicine and if profitable, will probably be made accessible to the sufferers at an reasonably priced value.
CSIR and Hyderabad-based Laxai Life Sciences Pvt Ltd have been given regulatory approval by Medicine Controller Basic of India (DCGI) to undertake a two-arm phase-II medical trial to evaluate the security and efficacy of the drug Colchicine within the enchancment of medical outcomes through the therapy of Covid-19 sufferers.
The accomplice CSIR institutes on this essential medical trial are the CSIR-Indian Institute of Chemical Know-how (IICT), Hyderabad and CSIR-Indian Institute of Integrative Drugs (IIIM), Jammu.
Director Basic of CSIR Dr Shekhar C. Mande expressed his happiness on the approval granted to conduct the medical trial on this permitted drug.
Dr Ram Vishwakarma, advisor to DG-CSIR, highlighted that Colchicine together with normal of care shall be an essential therapeutic intervention for Covid sufferers with cardiac co-morbidities and likewise for decreasing pro-inflammatory cytokines, resulting in quicker restoration.
Dr S. Chandrasekhar (Director CSIR-IICT, Hyderabad) and Dr D.S. Reddy (Director, CSIR-IIIM, Jammu), the 2 accomplice institutes from CSIR stated that they’re trying ahead to the result of this Part II medical efficacy trial on Colchicine, which can result in life-saving intervention within the administration of hospitalized sufferers.
Dr Ram Upadhayay, CEO, Laxai, knowledgeable, that the enrollment of sufferers has already begun at a number of websites throughout India and the trial is more likely to be accomplished within the subsequent 8-10 weeks.
He additional added that this drug could be made accessible to massive inhabitants of India based mostly on the outcomes of this trial and regulatory approval.
Current medical research have reported in main medical journals about colchicine being related to a major discount within the charges of recurrent pericarditis, post-pericardiotomy syndrome, and peri-procedural atrial fibrillation following cardiac surgical procedure and atrial fibrillation ablation.